According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “
Separately, Chardan Capital started coverage on OncoCyte Corp in a report on Thursday, February 23rd. They issued a buy rating and a $6.50 price target for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. OncoCyte Corp has an average rating of Buy and an average target price of $6.81.
Shares of OncoCyte Corp (NYSEMKT:OCX) traded up 5.000% during trading on Friday, hitting $5.775. 7,475 shares of the company traded hands. The company has a 50-day moving average of $5.41 and a 200-day moving average of $5.39. OncoCyte Corp has a 52-week low of $3.10 and a 52-week high of $7.95. The stock’s market capitalization is $169.56 million.
OncoCyte Corp (NYSEMKT:OCX) last announced its quarterly earnings data on Monday, February 27th. The company reported ($0.11) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.11). Equities analysts expect that OncoCyte Corp will post ($0.49) EPS for the current year.
Your IP Address:
OncoCyte Corp Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.